These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

616 related articles for article (PubMed ID: 30192094)

  • 41. Comparative Analysis of Deutetrabenazine and Valbenazine as VMAT2 Inhibitors for Tardive Dyskinesia: A Systematic Review.
    Golsorkhi M; Koch J; Pedouim F; Frei K; Bondariyan N; Dashtipour K
    Tremor Other Hyperkinet Mov (N Y); 2024; 14():13. PubMed ID: 38497033
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Neuromotor Adverse Effects in 342 Youth During 12 Weeks of Naturalistic Treatment With 5 Second-Generation Antipsychotics.
    Carbon M; Kapoor S; Sheridan E; Al-Jadiri A; Azzo S; Sarkaria T; Kane JM; Saito E; Correll CU
    J Am Acad Child Adolesc Psychiatry; 2015 Sep; 54(9):718-727.e3. PubMed ID: 26299293
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Aripiprazole in schizophrenia and schizoaffective disorder: A review.
    Stip E; Tourjman V
    Clin Ther; 2010; 32 Suppl 1():S3-20. PubMed ID: 20152550
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Switching to amisulpride.
    Peuskens J
    Curr Med Res Opin; 2002; 18 Suppl 3():s23-8. PubMed ID: 12418609
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Tardive Dyskinesia: New Treatments Available.
    Limandri BJ
    J Psychosoc Nurs Ment Health Serv; 2019 May; 57(5):11-14. PubMed ID: 31042295
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The Nithsdale schizophrenia surveys. IX: Akathisia, parkinsonism, tardive dyskinesia and plasma neuroleptic levels.
    McCreadie RG; Robertson LJ; Wiles DH
    Br J Psychiatry; 1992 Jun; 160():793-9. PubMed ID: 1352165
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Anticholinergics in the era of atypical antipsychotics: short-term or long-term treatment?
    Desmarais JE; Beauclair L; Margolese HC
    J Psychopharmacol; 2012 Sep; 26(9):1167-74. PubMed ID: 22651987
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Treatment recommendations for extrapyramidal side effects associated with second-generation antipsychotic use in children and youth.
    Pringsheim T; Doja A; Belanger S; Patten S;
    Paediatr Child Health; 2011 Nov; 16(9):590-8. PubMed ID: 23115503
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The nosology of tardive syndromes.
    Frei K; Truong DD; Fahn S; Jankovic J; Hauser RA
    J Neurol Sci; 2018 Jun; 389():10-16. PubMed ID: 29433810
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Other Antidepressants.
    Schwasinger-Schmidt TE; Macaluso M
    Handb Exp Pharmacol; 2019; 250():325-355. PubMed ID: 30194544
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Comparing tolerability of olanzapine in schizophrenia and affective disorders: a meta-analysis.
    Moteshafi H; Zhornitsky S; Brunelle S; Stip E
    Drug Saf; 2012 Oct; 35(10):819-36. PubMed ID: 22967188
    [TBL] [Abstract][Full Text] [Related]  

  • 52. EPS profiles: the atypical antipsychotics are not all the same.
    Weiden PJ
    J Psychiatr Pract; 2007 Jan; 13(1):13-24. PubMed ID: 17242588
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Benefits and limits of anticholinergic use in schizophrenia: focusing on its effect on cognitive function.
    Ogino S; Miyamoto S; Miyake N; Yamaguchi N
    Psychiatry Clin Neurosci; 2014 Jan; 68(1):37-49. PubMed ID: 24102938
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Valbenazine and Deutetrabenazine for Tardive Dyskinesia.
    Touma KTB; Scarff JR
    Innov Clin Neurosci; 2018 Jun; 15(5-6):13-16. PubMed ID: 30013814
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Neuroleptic reduction and/or cessation and neuroleptics as specific treatments for tardive dyskinesia.
    McGrath JJ; Soares KV
    Cochrane Database Syst Rev; 2000; (2):CD000459. PubMed ID: 10796546
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Antipsychotic-induced extrapyramidal side effects: A systematic review and meta-analysis of observational studies.
    Ali T; Sisay M; Tariku M; Mekuria AN; Desalew A
    PLoS One; 2021; 16(9):e0257129. PubMed ID: 34506552
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Valbenazine and deutetrabenazine: Vesicular monoamine transporter 2 inhibitors for tardive dyskinesia.
    Khorassani F; Luther K; Talreja O
    Am J Health Syst Pharm; 2020 Jan; 77(3):167-174. PubMed ID: 31974564
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Not Available].
    Pringsheim T; Doja A; Belanger S; Patten S
    Paediatr Child Health; 2012 Oct; 17(Suppl B):22B-30B. PubMed ID: 24082814
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Standard technical specifications for methacholine chloride (Methacholine) bronchial challenge test (2023)].
    ; ;
    Zhonghua Jie He He Hu Xi Za Zhi; 2024 Feb; 47(2):101-119. PubMed ID: 38309959
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Movement side effects of antipsychotic drugs in adults with and without intellectual disability: UK population-based cohort study.
    Sheehan R; Horsfall L; Strydom A; Osborn D; Walters K; Hassiotis A
    BMJ Open; 2017 Aug; 7(8):e017406. PubMed ID: 28775195
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.